Old Articles: <Older 7741-7750 Newer> |
|
The Motley Fool July 29, 2011 Brian Orelli |
2 Biotechs, 1 Promising Cancer Drug Perifosine on the home stretch. |
The Motley Fool July 29, 2011 Brian Orelli |
Merck's Making All the Right Long-Term Moves Job cuts, but they're not in research. |
The Motley Fool July 29, 2011 Brian Orelli |
Bristol-Myers Grows in the Wrong Places Bristol-Myers has a solid quarter, but Plavix and currency movements aren't important. |
The Motley Fool July 29, 2011 Brian Orelli |
Vroom! There Goes Vertex Vertex Pharmaceuticals' Incivek launch is off to a good start. |
The Motley Fool July 29, 2011 Seth Jayson |
A Hidden Reason That Community Health Systems' Earnings Are Outstanding Considering the numbers on a quarterly basis, the cash conversion cycle trend at Community Health Systems looks good. |
The Motley Fool July 29, 2011 Brian Orelli |
Boston Scientific Shows Me The company has shown it can hit its mark for at least one quarter, but can it last? |
The Motley Fool July 28, 2011 Seth Jayson |
Why Medicis Pharmaceutical May Be About to Take Off Is the current inventory situation at Medicis Pharmaceutical out of line? |
The Motley Fool July 28, 2011 Seth Jayson |
Here's How athenahealth Is Making You So Much Cash athenahealth's cash flows look clean. |
The Motley Fool July 28, 2011 Melly Alazraki |
J&J or Novartis? Novartis' businesses are an investor's delight; J&J's improving but isn't there yet. |
The Motley Fool July 28, 2011 Seth Jayson |
One Reason Sirona Dental Systems May Be Headed for a Slowdown Investors should check in with Sirona Dental Systems's filings to make sure there's a good reason for packing the storeroom for this period. |
<Older 7741-7750 Newer> Return to current articles. |